Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Tax Provisions (2021 - 2025)

Harmony Biosciences Holdings' Tax Provisions history spans 5 years, with the latest figure at $18.3 million for Q4 2025.

  • For Q4 2025, Tax Provisions rose 279.76% year-over-year to $18.3 million; the TTM value through Dec 2025 reached $56.4 million, up 91.34%, while the annual FY2025 figure was $56.4 million, 91.34% up from the prior year.
  • Tax Provisions for Q4 2025 was $18.3 million at Harmony Biosciences Holdings, up from $16.6 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $81.9 million in Q4 2022 and bottomed at -$80.0 million in Q3 2022.
  • The 5-year median for Tax Provisions is $9.9 million (2025), against an average of $7.5 million.
  • The largest YoY upside for Tax Provisions was 4553.55% in 2022 against a maximum downside of 8766.52% in 2022.
  • A 5-year view of Tax Provisions shows it stood at $1.8 million in 2021, then skyrocketed by 4553.55% to $81.9 million in 2022, then crashed by 84.04% to $13.1 million in 2023, then plummeted by 177.71% to -$10.2 million in 2024, then soared by 279.76% to $18.3 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Tax Provisions are $18.3 million (Q4 2025), $16.6 million (Q3 2025), and $9.9 million (Q2 2025).